Clinical trials: Mental Disorder
Depressive Disorder, Major
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.
- Trial name
- NCT01564862
- Testing
- vortioxetine (Lu AA21004), Duloxetine
- Where
- 92 sites in United States, Bulgaria and 5 more
- Volunteers
- 602 people
- Sponsor
- Takeda
Chronic Pain, Appetite Disorders
The JULI Registry--Hemp and Cannabis Observational Registry
The JuLi Registry seeks to fill some of the gaps associated with the clinical use of CBD (cannabidiol) and other cannabinoid formulations including THC and others.
- Conditions
- Chronic Pain, Appetite Disorders, Neuropathy, Menopausal Syndrome
- Trial name
- JULI (NCT04726254)
- Where
- 4 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Juva Life
Healthy
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects.
- Trial name
- NCT01530529
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
A Study in Depression and Associated Painful Physical Symptoms
The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than…
- Trial name
- NCT01070329
- Testing
- Duloxetine
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 527 people
- Sponsor
- Eli Lilly and Company
Acute Psychotic Episode, Schizophrenia
Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia
This is an observational study describing the real-life antipsychotic treatment during the hospitalisation of the patients due to acute psychotic episode.
- Trial name
- NCT01491412
- Where
- 14 sites in Hungary, Latvia and 1 more
- Volunteers
- 503 people
- Sponsor
- AstraZeneca
Schizophrenia
First Time in Human Study (FTIH) With Positron Emission Tomography (PET)
This study described in the present protocol consists of two sections. Part A is the first administration into man to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK1144814.
- Trial name
- NCT01381419
- Testing
- GSK1144814
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Insomnia
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.
- Trial name
- NCT06498128
- Testing
- Daridorexant, Non-orexin receptor antagonist medications for insomnia, No insomnia medication
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Dementia
Discovering Factors in the Clinical Trial Journey of Dementia Patients
This research aims to collect comprehensive data on the clinical trial experience of dementia patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully.
- Trial name
- NCT05850000
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Stress, Insomnia
A Clinical Trial of De-Stress & Snooze Gummies in Reducing Stress and Insomnia Disorder
The current study focuses on clinical validation of efficacy of nutraceutical product in management of sleep disorder. Improved sleep quality contributes significantly to cognitive function.
- Conditions
- Stress, Insomnia, Quality of Life
- Trial name
- NCT06571331
- Testing
- De-Stress & Snooze Gummies-U001, De-Stress & Snooze Gummies-I001
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Herbolab India Pvt. Ltd.
Attention Deficit Disorder With Hyperactivity
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.
- Trial name
- NCT03006367
- Testing
- NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Major Depressive Disorder
Ketamine for Major Depressive Disorder
The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.
- Trial name
- NCT03721900
- Testing
- SHX-001 Active low dose, SHX-001 Active High dose
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shenox Pharmaceuticals, LLC
Insomnia
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel…
- Trial name
- NCT00525941
- Testing
- NBI-34060
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Alzheimer Disease
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
A two-year safety study of simufilam (PTI-125) 100 mg oral tablets twice daily for participants of the previous simufilam studies as wells as additional new mild-to-moderate Alzheimer's disease subjects for a total of 200…
- Trial name
- PTI-125 (NCT04388254)
- Testing
- Simufilam 100 mg oral tablet
- Where
- 17 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Cassava Sciences, Inc.
Schizophrenia
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
- Trial name
- DayBreak (NCT02717195)
- Testing
- Risperidone, Olanzapine, Lu AF35700
- Where
- 147 sites in United States, Bulgaria and 12 more
- Volunteers
- 1,098 people
- Sponsor
- H. Lundbeck A/S
Treatment Resistant Depression (TRD)
Parcel-guided rTMS for Major Depressive Disorder
Study comparing standard repetitive transcranial magnetic stimulation (rTMS) for Depression to a novel targeting approach using brain surface parcellation to locate a specific brain target.
- Trial name
- NCT07287839
- Testing
- Accelerated rTMS, Parcel-guided Accelerated rTMS
- Volunteers
- 60 people
- Sponsor
- Soterix Medical
Alzheimer Disease
Multiple Ascending Dose Study of ALZ-801
Phase I, single-center, double-blind, randomized, placebo-controlled, parallel-group study of the safety, tolerability, and pharmacokinetics (PK) in plasma and urine, of multiple ascending doses of ALZ-801 (capsule, Part 1…
- Trial name
- NCT04157712
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Alzheon Inc.
Major Depressive Disorder
Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)
Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)
- Trial name
- CTO-TNS (NCT02805881)
- Testing
- Neurolief system
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Neurolief Ltd.
Sleep Disorders
Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA
Primary Objective: To evaluate the efficacy and safety of the use of Stilnox CR in Mexican patients with chronic insomnia at the prescription conditions of daily practice Secondary Objective: To evaluate the satisfaction of the…
- Trial name
- NCT01024192
- Testing
- ZOLPIDEM SL800750
- Where
- Mexico
- Volunteers
- 135 people
- Sponsor
- Sanofi
Bipolar Disorder
Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fasting conditions using a…
- Trial name
- NCT00601536
- Testing
- Lithium
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.